118 related articles for article (PubMed ID: 21620296)
1. [The role of chemotherapy in the management of bladder cancer].
Ismaili N; Amzerin M; Elmajjaoui S; Droz JP; Flechon A; Errihani H
Prog Urol; 2011 Jun; 21(6):369-82. PubMed ID: 21620296
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
Lehmann J; Retz M; Stöckle M
World J Urol; 2002 Aug; 20(3):144-50. PubMed ID: 12196897
[TBL] [Abstract][Full Text] [Related]
3. Update on chemotherapy for advanced bladder cancer.
Rosenberg JE; Carroll PR; Small EJ
J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer.
Calabrò F; Sternberg CN
Eur Urol; 2009 Feb; 55(2):348-58. PubMed ID: 18977070
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
7. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
[TBL] [Abstract][Full Text] [Related]
8. The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience.
Serretta V; Lo Greco G; Pavone C; Pavone-Macaluso M
J Urol; 1998 Apr; 159(4):1187-91. PubMed ID: 9507829
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
10. Bladder cancer.
Barocas DA; Clark PE
Curr Opin Oncol; 2008 May; 20(3):307-14. PubMed ID: 18391631
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant chemotherapy (M-VAC) for locally invasive bladder cancer].
Kamoto T; Kawakita M; Okabe T; Matsumoto M; Matsuda T; Yoshida O
Hinyokika Kiyo; 1992 Apr; 38(4):405-11. PubMed ID: 1529813
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
[TBL] [Abstract][Full Text] [Related]
14. Bladder cancer.
Gwynn ES; Clark PE
Curr Opin Oncol; 2006 May; 18(3):277-83. PubMed ID: 16552241
[TBL] [Abstract][Full Text] [Related]
15. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
16. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
[TBL] [Abstract][Full Text] [Related]
17. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
18. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
[TBL] [Abstract][Full Text] [Related]
20. Perioperative chemotherapy for bladder cancer.
Sonpavde G; Petrylak DP
Crit Rev Oncol Hematol; 2006 Feb; 57(2):133-44. PubMed ID: 15990329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
